- 5mmcfd gas to be added to national grid from Kailashtila gas field |
- ArmArmed Forces Day: Tarique's message draws on historic closeness |
- UNGA urges renewed int’l efforts for a resolution of Rohingya crisis |
- First National AI Readiness Assessment Report Published |
- China calls for implementation roadmap for new finance goal |
Study on dengue vaccine led by icddr,b and UVM shows promise
Dengue patients under treatment at a hospital on Sunday.
Investigators from icddr,b and the Larner College of Medicine at the University of Vermont (UVM), USA are the first to study a promising tetravalent dengue vaccine in dengue-endemic Bangladesh.
Their work, evaluating the single-dose tetravalent dengue vaccine candidate TV005, demonstrated safety and immune responsiveness in children and adults. The accompanying study was recently published in the journal The Lancet Infectious Diseases.
Investigators followed almost 200 volunteers in four age cohorts (ages 1-49 years) who received the TV005 vaccine or placebo over the course of three years, beginning in 2016. TV005 was shown to be well-tolerated. Antibodies to all four dengue serotypes were found in most volunteers after vaccination; individuals who had been infected previously with dengue had higher antibody counts. – icddr,b release